Publication:
United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

Issued Date

2020-04-01

Resource Type

Article

ISSN

1464410X
14644096

DOI

10.1111/bju.14980

Other identifier(s)

2-s2.0-85078843339

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

BJU International. Vol.125, No.4 (2020), 541-552

Suggested Citation

Hirotsugu Uemura, Dingwei Ye, Ravindran Kanesvaran, Edmund Chiong, Bannakij Lojanapiwat, Yeong Shiau Pu, Sudhir Kumar Rawal, Azad Hassan Abdul Razack, Hao Zeng, Byung Ha Chung, Noor Ashani Md Yusoff, Chikara Ohyama, Choung Soo Kim, Sunai Leewansangtong, Yuh Shyan Tsai, Yanfang Liu, Weiping Liu, Maximiliano van Kooten Losio, Marxengel Asinas-Tan United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. BJU International. Vol.125, No.4 (2020), 541-552. doi:10.1111/bju.14980 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/54613

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

Author(s)

Hirotsugu Uemura
 Dingwei Ye
 Ravindran Kanesvaran
 Edmund Chiong
 Bannakij Lojanapiwat
 Yeong Shiau Pu
 Sudhir Kumar Rawal
 Azad Hassan Abdul Razack
 Hao Zeng
 Byung Ha Chung
 Noor Ashani Md Yusoff
 Chikara Ohyama
 Choung Soo Kim
 Sunai Leewansangtong
 Yuh Shyan Tsai
 Yanfang Liu
 Weiping Liu
 Maximiliano van Kooten Losio
 Marxengel Asinas-Tan

Other Contributor(s)

Fudan University Shanghai Cancer Center
 Celgene International Sàrl
 Severance Hospital
 Kindai University
 West China School of Medicine/West China Hospital of Sichuan University
 National Cheng Kung University Hospital
 National Taiwan University Hospital
 Janssen Research & Development
 Hirosaki University
 National Cancer Centre, Singapore
 National University Hospital, Singapore
 University of Malaya
 Kuala Lumpur Hospital
 Faculty of Medicine, Siriraj Hospital, Mahidol University
 Johnson & Johnson
 University of Ulsan, College of Medicine
 Chiang Mai University
 Rajeev Gandhi Cancer Institutes
 Medical Affairs
 Medical Affairs

Abstract

© 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International Objectives: To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real-world practice in Asia using the United in Fight against prOstate cancer (UFO) registry. Patients and Methods: We established a multi-national, longitudinal, observational registry of patients with prostate cancer presenting to participating tertiary care hospitals in eight Asian countries. A total of 3636 eligible patients with existing or newly diagnosed high-risk localised prostate cancer (HRL), non-metastatic biochemically recurrent prostate cancer (M0), or metastatic prostate cancer (M1), were consecutively enrolled and are being followed-up for 5 years. Patient history, demographic and disease characteristics, treatment and treatment decisions, were collected at first prostate cancer diagnosis and at enrolment. Patient-reported quality of life was prospectively assessed using the European Quality of Life-five Dimensions, five Levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy for Prostate Cancer questionnaires. In the present study, we report the first interim analysis of 2063 patients enrolled from study start (15 September 2015) until 18 May 2017. Results: Of the 2063 enrolled patients, 357 (17%), 378 (19%), and 1328 (64%) had HRL, M0 or M1 prostate cancer, respectively. The mean age at first diagnosis was similar in each group, 56% of all patients had extracapsular extension of their tumour, 28% had regional lymph node metastasis, and 53% had distant metastases. At enrolment, 62% of patients had at least one co-morbidity (mainly cardiovascular disease or diabetes), 91.8% of M1 patients had an Eastern Cooperative Oncology Group performance score of <2 and the mean EQ-5D-5L visual analogue score was 74.6–79.6 across cohorts. Treatment of M1 patients was primarily with combined androgen blockade (58%) or androgen-deprivation therapy (either orchidectomy or luteinising hormone-releasing hormone analogues) (32%). Decisions to start therapy were mainly driven by treatment guidelines and disease progression. Decision to discontinue therapy was most often due to disease progression (hormonal drug therapy) or completion of therapy (chemotherapy). Conclusion: In the UFO registry of advanced prostate cancer in Asia, regional differences exist in prostate cancer treatment patterns that will be explored more deeply during the follow-up period; prospective follow-up is ongoing. The UFO registry will provide valuable descriptive data on current disease characteristics and treatment landscape amongst patients with prostate cancer in Asia.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/123456789/54613

Collections

Scopus 2020